Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer

May combine two claims.

Over 95% of patients with HNSCC and 57.4% of patients with CRC have persistent aberrant STAT3 activation.

“This is especially the case in over 95% of patients with head and neck squamous cell carcinoma (HNSCC) and 57.4% of patients with colorectal cancer (CRC) (3–5).”

• cites [3] Geiger, 2016, The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations, Oral Oncol sourcePartly supported

  The “STAT3 activation in HNSCC” section describes STAT3 signaling activation as near-universal in HNSCC, supporting the broad HNSCC point but not specifying a rate above 95%. It mentions colorectal cancer models, but does not report that 57.4% of patients with colorectal cancer have persistent aberrant STAT3 activation. Page numbers are not available in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [4] Kusaba, 2006, Activation of STAT3 is a marker of poor prognosis in human colorectal cancer, Oncol Rep sourceSupported
• cites [5] sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

PROTAC technology has been widely used to specifically flag transcription factors for degradation.

“Proteolysis targeting chimeric (PROTAC) technology has been widely used to specifically flag transcription factors for degradation (22).”

• cites [22] sourcePartly supported

  The Introduction describes PROTACs as suitable for targeting transcription factors, and the Conclusion reports proof-of-concept TF-PROTACs that degraded p65 and E2F1 in cells. The paper does not establish that PROTAC technology has been widely used to degrade transcription factors; it presents this application as a developing approach. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

SD-36 can effectively simulate degradation of STAT3 protein in leukemia cells.

“The PROTAC molecule SD-36 (26), developed by the Wang group with structure-based design, can effectively simulate the degradation of STAT3 protein in leukemia cells.”

• cites [26] sourceSupported

May combine two claims.

PROTAC adopts event-driven pharmacology binding at any point within the structure of potential targets, unlike occupancy-mode small molecule inhibitors.

“Unlike the occupancy mode of small molecule inhibitors, which increase the risk of off-target effects, PROTAC adopts the pattern of “event-driven” pharmacology binding at any point within the structure of potential targets (23, 24).”

• cites [23] sourcePartly supported

  The Introduction and Fig. 1 caption in “Advantages of using PROTACs over other approaches to inhibit a POI” describe PROTACs’ catalytic degradation of targets, in contrast to inhibitors that typically bind an active site. Table 1 also says PROTACs can target proteins without an active binding site. These passages support the event-driven contrast, but not the unrestricted claim that PROTACs can bind at any point within a target’s structure. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [24] sourceSupported

Classified as probably not a substantial claim. May combine two claims.

PDX models recapitulate the biological property and molecular heterogeneity of human cancers and are an ideal preclinical model for inferring clinical performance.

“PDX models that recapitulate the biological property and molecular heterogeneity of human cancers have been considered as an ideal preclinical model for inferring clinical performance (6, 43)”

• cites [6] sourcePartly supported

  The Discussion (page not provided) reports that PDX drug responses can mimic clinical-trial responses, supporting their use in preclinical evaluation. It also says this study did not compare matched patient tumors and PDXs at the molecular level and notes limitations including mouse-specific tumor evolution. It therefore does not establish that PDXs generally preserve the molecular heterogeneity of human cancers or are an ideal model for predicting clinical performance. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [43] sourcePartly supported

  The Results section (page unavailable) reports that HNSCC PDXs showed genomic fidelity to their primary tumors and that one PDX’s trametinib response paralleled its patient’s response. It does not establish that PDXs generally retain the molecular heterogeneity of human cancers or are an ideal model for predicting clinical performance. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

STAT3 controls the malignant behavior of tumor cells and dictates the responsiveness to radio- and chemotherapy.

“It has also been reported that STAT3 controls the malignant behavior of tumor cells, while it dictates the responsiveness to radio- and chemotherapy (56).”

• cites [56] sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

TSN possesses antitumor effects in various cancers by regulating c-Myc, PI3K/AKT/mTOR, and NF-κB, which are strongly correlated with STAT3.

“Recent studies have shown that TSN possesses antitumor effects in various cancers, such as triple-negative breast cancer (TNBC), glioma, ovarian cancer, liver cancer, CRC, by regulating c-Myc, PI3K/AKT/mTOR, and NF-κB, which are strongly correlated with STAT3 (52–55).”

• cites [52] sourceNot checked — no full text of the source
• cites [53] sourcePartly supported

  The Results section reports that TSN inhibited PI3K/Akt/mTOR signaling in glioma cells, and the Discussion notes reports of antitumor effects in other malignancies. This paper does not establish that TSN acts through c-Myc or NF-κB, or that the mechanisms claimed are strongly correlated with STAT3. (LLM, conf=0.89)

  Experimental — accuracy not yet measured
• cites [54] sourceNot checked — no full text of the source
• cites [55] sourceNot checked — no full text of the source

Classified as probably not a substantial claim. May combine two claims.

Zhang et al. reported that TSN directly bound to the SH2 domain of STAT3 with a Kd value of 240 nM, leading to impediment of oncogenic processes in osteosarcoma.

“Zhang et al. also reported that TSN directly bound to the SH2 domain of STAT3 with a Kd value of 240 nM, leading to the impediment of various oncogenic processes in osteosarcoma (32)”

• cites [32] sourceSupported

May combine two claims.

PROTAC molecules exhibit improved therapeutic efficacy and minimized drug resistance because of the potential for unique catalytic recycling.

“Third, PROTAC molecules exhibit improved therapeutic efficacy and minimized drug resistance because of the potential for unique catalytic recycling (23, 24).”

• cites [23] sourcePartly supported

  The Introduction (page unavailable) says PROTACs act catalytically, can produce stronger and longer-lasting effects than small-molecule inhibitors, and can overcome certain forms of inhibitor resistance. It presents these as potential advantages, not established improvements in therapeutic efficacy or a general minimization of resistance caused by catalytic recycling. The Conclusions (page unavailable) also report that resistance to some PROTACs has occurred after chronic treatment. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [24] sourcePartly supported

  The Small-molecule PROTACs section reports that non-covalent PROTACs act catalytically, may require less drug exposure, and showed superior efficacy to parent inhibitors in mouse tumor xenografts. It also says protein removal can counteract compensatory accumulation associated with inhibitors, but does not establish that catalytic recycling minimizes drug resistance or that improved therapeutic efficacy has been demonstrated clinically. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Wang et al. developed SD-36, a degrader that targeted STAT3 in leukemia and lymphoma cells.

“In 2019, Wang et al. developed SD-36, a degrader that targeted STAT3 in leukemia and lymphoma cells (26).”

• cites [26] sourceSupported

May combine two claims.

Aberrant STAT3 activation has been implicated in tumor initiation and progression, and preclinical evidence supports STAT3 as a potential treatment target in STAT3-dependent epithelial cancer.

“Aberrant STAT3 activation has been implicated in tumor initiation and progression, and preclinical evidence strongly supports STAT3 as a potential treatment target in STAT3-dependent epithelial cancer (1, 3, 46).”

• cites [1] sourcePartly supported

  The Introduction links STAT3 activation to oncogenesis and tumor progression, and the Conclusions describe efforts to develop STAT3-targeted therapies. The paper does not specifically state that strong preclinical evidence supports treatment of STAT3-dependent epithelial cancer; it also cautions that STAT3’s role depends on tumor type and cellular context. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [3] Geiger, 2016, The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations, Oral Oncol sourceSupported
• cites [46] sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

STAT3 partially coordinates the cisplatin-resistance phenotype in non-small-cell lung cancer.

“In addition, STAT3 partially coordinates the cisplatin-resistance phenotype in non–small-cell lung cancer, providing support for the combination of cisplatin, rapamycin, and STAT3 abrogation as a rational therapeutic approach for lung cancer (57).”

• cites [57] sourcePartly supported

  The Results section ('ATM up-regulate PD-L1 through JAK1,2/STAT3 pathway') reports increased STAT3 signaling in cisplatin-resistant NSCLC cells and reduced invasion when STAT3 was inhibited. This supports a role for STAT3 in features of those cells, but the paper does not show that STAT3 inhibition reverses cisplatin resistance or test the proposed cisplatin–rapamycin–STAT3 combination. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

TSM-1 exhibits superior selectivity, potency, and robust antitumor effects in STAT3-dependent HNSCC and CRC, especially in PDX and PDO models.

“The optimized lead PROTAC (TSM-1) exhibits superior selectivity, potency, and robust antitumor effects in STAT3-dependent HNSCC and CRC — especially in clinically relevant patient-derived xenografts (PDX) and patient-derived organoids (PDO).”

May combine two claims.

TSM-1 increased IL-2, TNF-α, and IFN-γ in tumor tissues, showing T cell activation and infiltrates.

“To detect the effects of TSM-1 on T cells in vivo, the expression levels of IL-2, TNF-α, and IFN-γ in tumor tissues have been detected by ELISA kit, and results indicate that TSM-1 could increase these cytokines, showing T cell activation and infiltrates.”

May combine two claims.

TSN-treated mice died: 2 of 5 HN6, 1 of 5 HCT116, and 2 of 5 CT26 tumor-bearing mice died on days 11, 6, and 4 respectively.

“In contrast, 2 HN6 tumor-bearing mice (2 of 5), 1 HCT116 tumor-bearing mice (1 of 5), and 2 CT26 tumor-bearing mice (2 of 5) died on the eleventh, sixth, and fourth day following TSN administration, respectively (Figure 7, A, E, and I).”

May combine two claims.

MG132 suppressed TSM-1-induced STAT3 downregulation in CAL33 and HCT116 cells, supporting proteasome-dependent STAT3 degradation.

“In the presence of MG132, the TSM-1–induced STAT3 downregulation in CAL33 (Figure 6, C and I) and HCT116 (Figure 6, D and J) cells was suppressed, supporting proteasome-dependent STAT3 degradation.”

May combine two claims.

Lenalidomide alone had no effect on STAT3 protein levels, while excess lenalidomide blocked TSM-1-induced STAT3 degradation in CAL33 and HCT116 cells, suggesting CRBN-dependent degradation.

“Moreover, lenalidomide alone had no effect on the levels of STAT3 protein in cells, while preincubation with excess amount of lenalidomide blocked the degradation of STAT3 that was induced by TSM-1 in CAL33 (Figure 6, E and K) and HCT116 (Figure 6, F and L) cells, suggesting that TSM-1 induced STAT3 degradation in a CRBN-dependent manner.”

• AssumptionRests on an assumption: CRBN is expressed and functional in the HNSCC and CRC cell lines and tumors used.

May combine two claims.

TSM-1 (2 mg/kg) induced significant tumor regression and reduced tumor weight without affecting bodyweight in HN6, HCT116, and CT26 xenograft models.

“In comparison with the control group, TSM-1 (2 mg/kg) induced significant tumor regression (Figure 7, B, F, and J) and reduced tumor weight (Figure 7, D, H, and L) without affecting the bodyweight of the mice (Figure 7, C, G, and K).”

May combine two claims.

HT29 cells had high STAT3 level but were not sensitive to TSM-1 at these concentrations.

“Although STAT3 level was also high in HT29 cells, the HT29 cells were not sensitive to TSM-1 at these concentrations.”

May combine two claims.

STAT3 protein levels in CAL33 and HN6 cells were higher than other HNSCC cell lines, consistent with their response to TSM-1 treatment.

“Specifically, STAT3 protein levels in CAL33 and HN6 cells were higher than the other HNSCC cell lines, which were consistent with their response to the TSM-1 treatment (Figure 3C).”

May combine two claims.

TSN induced acute inflammatory response, indicating tissue damage.

“To further explore the mechanism of toxicity of TSN, we detected the blood routine in CT26 tumor-bearing models and found that TSN could induce acute inflammatory response, indicating tissue damage.”

May combine two claims.

In 293T cells, TSM-1 treatment (1 μM, 36 hours) reduced STAT3 protein and increased the abundance of ubiquitinated STAT3 protein.

“In 293T cells, TSM-1 treatment (1 μM, 36 hours) could reduce the level of STAT3 protein, while increasing the abundance of ubiquitinated STAT3 protein (Figure 6, M and N).”

May combine two claims.

TSM-1 (3 μM) induced STAT3 protein degradation in a time-dependent manner, with STAT3 levels decreased to 29.55% or 10.03%.

“An immunofluorescence-based time course study revealed that TSM-1 (3 μM) induced STAT3 protein degradation in a time-dependent manner (Figure 4G and Supplemental Figure 4E), and STAT3 protein levels decreased to 29.55% or 10.03%.”

May combine two claims.

TSM-1 significantly induced an increase in the percentage of S phase in CAL33, SCC7, DLD-1, and CT26 cells, accompanied by a decrease in G0/G1 phase cells.

“TSM-1 could significantly induce the increase in the percentage of S phase in CAL33 (Figure 5A and Supplemental Figure 6A), SCC7 (Supplemental Figure 8, F and G), DLD-1 cell lines (Supplemental Figure 5C and Supplemental Figure 7A), and CT26 (Supplemental Figure 8, C and G), accompanied by a decrease in the percentage of G0/G1 phase cells.”

May combine two claims.

TSM-Me could not effectively inhibit tumor cell viability and induce STAT3 degradation compared with TSM-1.

“However, TSM-Me could not effectively inhibit tumor cell viability and induce STAT3 degradation compared with TSM-1 (Supplemental Figure 11, A, B, D, and E).”

May combine two claims.

TSM-Me lost the ability to recruit CRBN but still exhibited strong affinity with STAT3 (Kd = 239 nM).

“Although TSM-Me lost the ability to recruit CRBN, it still exhibited strong affinity with STAT3 (Kd = 239 nM; Supplemental Figure 11C).”

May combine two claims.

TSM-1 caused significant cycle arrest in G2 phase on HCT116 cells and in G0/G1 phase on HN6 cells.

“In addition, TSM-1 caused a significant cycle arrest in G2 phase on HCT116 cells (Figure 5C and Supplemental Figure 7A) and cell cycle arrest in G0/G1 phase on HN6 cells (Supplemental Figure 5A and Supplemental Figure 6A).”

May combine two claims.

TSN induced blurred myocardial fibroblasts, severe hyperemia in alveolar cavity, and a reduction of glomerular features.

“IHC staining of tumor tissues also showed that TSN induced blurred myocardial fibroblasts, severe hyperemia in alveolar cavity, and a reduction of glomerular features (Supplemental Figure 15).”

May combine two claims.

TSM-1 treatment effectively depleted STAT3 protein and reduced levels of p-STAT3, cyclinD, c-Myc, PD-L1, and BCL-XL.

“TSM-1 treatment could effectively deplete STAT3 protein and reduce the level of important downstream proteins, including p-STAT3, cyclinD, c-Myc, PD-L1, and BCL-XL.”

May combine two claims.

TSM-1 treatment led to an increase in necrotic tumor lesions and apoptotic-positive cells, a decrease in proliferating cells, and reduced STAT3 protein expression.

“Subsequent H&E staining, TUNEL assays, and IHC analyses of tumor sections showed that TSM-1 treatment also led to an increase in necrotic tumor lesions, apoptotic-positive cells, a decrease in the number of proliferating cells, and reduced STAT3 protein expression (Supplemental Figures 12–14)”

May combine two claims.

TSN or lenalidomide alone did not form green fluorescent drops.

“When 293T cells were treated with TSN or lenalidomide alone, respectively, there were no green fluorescent drops formed.”

May combine two claims.

Replacing the E3 ubiquitin ligase of TSM-1 with VHL seriously decreased solubility, resulting in poor efficacy on HNSCC and CRC cells.

“Next, we replaced the E3 ubiquitin ligase of TSM-1 with Von Hippel-Lindau (VHL) and found that the conjugation of VHL with TSN seriously decreased its solubility, resulting in poor efficacy on HNSCC and CRC cells, so TSM-1 was selected for further research.”

May combine two claims.

TSM-1 (5 mg/kg daily) inhibited PDX SCC486 tumor growth without obvious toxicity.

“The PDX model SCC486 exhibited a high degree of malignancy with rapid tumor growth after engraftment; TSM-1 (5 mg/kg, daily) could inhibit PDX SCC486 tumor growth without obvious toxicity (Figure 10, B–D).”

May combine two claims.

CAL33 and HCT116 exhibited specific STAT3 degradation among the STAT protein family after TSM-1 treatment, suggesting high selectivity of TSM-1.

“More importantly, CAL33 and HCT116 exhibited specific STAT3 degradation among the STAT protein family after treatment with TSM-1, suggesting the highly selective nature of TSM-1.”

May combine two claims.

TSM-1 exhibited enhanced potency and reduced toxicity compared with TSN to inhibit cancer cell proliferation/viability.

“In comparison to the prototype compound TSN used to construct TSM-1, the degrader TSM-1 exhibited enhanced potency and reduced toxicity to inhibit cancer cell proliferation/viability.”

May combine two claims.

TSN-treated mice displayed limited right hind limb movement, weight loss, and even death.

“By contrast, TSN-treated mice displayed limited right hind limb movement, weight loss, and even death.”

May combine two claims.

In xenograft models, TSM-1 inhibited tumor formation without an overt level of toxicity.

“In xenograft models, TSM-1 inhibited tumor formation without an overt level of toxicity.”

Probably not a substantial claim: may not pass S3 (load-bearing).

TSM-1 takes natural small molecules as lead compounds.

“This PROTAC molecule takes natural small molecules as lead compounds; they provide a powerful tool for oncology research and solid foundation for future drug discovery.”

May combine two claims.

TSM-1 led to more necrosis and TUNEL+ cells and less STAT3+ cells in PDX tumors.

“Histopathological examination showed that TSM-1 led to much more necrosis and TUNEL+ cells; moreover, such treatment resulted in less STAT3+ cells (Figure 10J and Supplemental Figure 20).”

May combine two claims.

STAT3 constitutively occupies the proximal region of the PD-L1 promoter and directly regulates PD-L1 expression.

“On the other hand, STAT3 constitutively occupies the proximal region of the PD-L1 promoter and directly regulates PD-L1 expression (36).”

• cites [36] sourceNot checked — no full text of the source

May combine two claims.

Increased STAT3 expression and activation are highly associated with HNSCC and CRC progression and may serve as prognostic biomarkers and potential therapeutic targets.

“Taken together, these results suggest that increased STAT3 expression and activation were highly associated with HNSCC and CRC progression and may serve as prognostic biomarkers and potential therapeutic targets.”

May combine two claims.

TSM-1 inhibited tumor growth by reducing STAT3 protein levels and suppressing its downstream signaling pathways.

“Taken together, TSM-1 inhibited tumor growth by reducing STAT3 protein levels and suppressing its downstream signaling pathways.”

May combine two claims.

TSM-1 could form ternary complexes during degradation, highly dependent on E3 ubiquitin ligase and STAT3 ligands, providing evidence that TSM-1 induced protein-to-protein interactions between STAT3 and CRBN.

“Taken together, these results demonstrate that TSM-1 could form ternary complexes during degradation, which were highly dependent on the E3 ubiquitin ligase and STAT3 ligands, providing further evidence that TSM-1 induced protein-to-protein interactions between STAT3 and CRBN.”

May combine two claims.

TSM-1 has a sustained and possibly catalytic effect on STAT3 degradation.

“Taken together, these results confirm the sustained and possibly catalytic effect of TSM-1 on STAT3 degradation.”

May combine two claims.

TSM-1 could greatly inhibit tumor growth and improve overall survival of 2 tumor models.

“indicating that TSM-1 could greatly inhibit tumor growth and improve overall survival of 2 tumor models.”

Classified as probably not a substantial claim.

Engagement of PD-L1 and PD-1 exerts inhibitory effects on T cells by inducing their apoptosis and anergy.

“The engagement of PD-L1 and PD-1 exerts inhibitory effects on T cells by inducing their apoptosis and anergy (36).”

• cites [36] sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

In the syngeneic and xenograft tumor models, mice were randomized into separate groups.

“When the tumor volume reached about 50 mm3, the mice/nude mice were randomized into separate groups according to the design (n = 5 per group): vehicle control, TSN, TSM-1, anti–PD-L1 antibody alone, and anti–PD-L1 antibody plus TSM-1.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The 293T, HCT116, DLD-1, HT29, and SW620 cell lines used in the study were authenticated.

“Authenticated 293T, HCT116, DLD-1, HT29, and SW620 cell lines were purchased from the Cell Bank of the Shanghai Institute of Cell Biology (SIBS), CAS.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Data are presented as mean + SD or mean ± SD from at least 3 independent experiments.

“Data are presented as mean + SD (bars) or mean ± SD (curves) from at least 3 independent experiments.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The STAT3/HOTAIR/EZH2 axis may serve as a novel therapeutic target for combination therapy of cisplatin and cetuximab to treat patients with HNSCC with PI3K activation.

“Moreover, X. Zhou proved that the STAT3/HOTAIR/EZH2 axis may serve as a novel therapeutic target for combination therapy of cisplatin and cetuximab to treat patients with HNSCC with PI3K activation (58).”

• cites [58] sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Chemo-gene therapy by combining PTX with STAT3 siRNA may be a practical strategy to effectively suppress tumor growth and metastasis.

“Luo et al. also verified that chemo-gene therapy by combining PTX, the first-line chemotherapeutic drug, with STAT3 siRNA may be a practical strategy to effectively suppress tumor growth and metastasis (59).”

• cites [59] sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S2 (checkable). May combine two claims.

TSM-1 provides a powerful tool for oncology research and a solid foundation for future drug discovery.

“they provide a powerful tool for oncology research and solid foundation for future drug discovery.”

Probably not a substantial claim: may not pass S2 (checkable). May combine two claims.

TSM-1, the PROTAC targeting STAT3 degradation, is expected to be used in combination with first-line therapeutic agents or targeted drugs in clinic to enhance the antitumor effect as well as overcoming drug resistance.

“Taken together, TSM-1, the PROTAC targeting STAT3 degradation, is expected to be used in combination with first-line therapeutic agents or targeted drugs in clinic to enhance the antitumor effect as well as overcoming drug resistance.”

• AssumptionRests on an assumption: Findings in the mouse models and cell lines used in this study are predictive of clinical outcomes in humans.

May combine two claims.

In PDX and PDO models, TSM-1 effectively inhibited tumor growth, demonstrating efficacy in clinically relevant tumor models and potential suitability for future translational development.

“In PDX and PDO models, TSM-1 effectively inhibited the growth of tumors, demonstrating the efficacy of TSM-1 in clinically relevant tumor models, as well as its potential suitability for future translational development.”